ClinicalTrials.gg
RecruitingNCT07385638Updated Jul 27, 2026

Olorofim in Early Coccidioidal Meningitis

A Phase 2 interventional study of olorofim in Coccidioidal Meningitis, sponsored by Fariba Donovan. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Fariba Donovan · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Coccidioidomycosis with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Coccidioidomycosis · United States.

Planned enrollment
9th of 11
12 · median 48
Started
2026
with 1 other
Phase 2
4 of 16
2 open now
Registered
15th of 16
by date
Lead sponsor
1 of 16
Fariba Donovan

Among the 16 studies in Coccidioidomycosis with a site in United States, this one is the 9th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 2, and was the 15th registered.

Coccidioidomycosis

21 studies on the registry are indexed under Coccidioidomycosis; 4 are open to participants now.

Browse Coccidioidomycosis studies →

Open to participants now

3 of the 16 studies in Coccidioidomycosis with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 2 Coccidioidomycosis studies recruiting now, 1 sets no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Coccidioidomycosis with a site in United States, or all of them as a file.
02

Study summary

This research study is being conducted to learn more about the use of olorofim in Coccidioidal (Cocci) meningitis, a rare but serious fungal infection that affects the brain and spinal cord. The study is exploratory, meaning that early information is being gathered to better understand the effectiveness of olorofim in coccidioidal meningitis in its early stages. The study plans to enroll approximately 10 to 12 participants who have been recently diagnosed-within the last 4 to 8 weeks-and who do not have a ventriculoperitoneal (VP) shunt, a medical device sometimes used to relieve pressure in the brain. Participants will be followed for approximately 6 months, during which health information will be collected to evaluate disease progression and response to treatment. Participants may have the opportunity to enroll in the olorofim Managed Access Program to continue treatment after completion of the study period.

03

Conditions studied

  • Coccidioidal Meningitis

Browse trials for

Keywords

  • coccidioidomycosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients aged ≥ 18 years and weighing ≥ 40 kg, able to understand and consent in English, who have been fully informed and:

    a) who have given voluntary written , or whose legally authorized representative(s) has been fully informed and has given voluntary written informed consent if applicable, and in compliance with local regulations OR

  2. b) who have given oral informed consent witnessed in writing by an independent person and in compliance with local regulations for patients who are unable to write and/or read but who fully understand the oral information given by the Investigator (or nominated representative).
  3. Ongoing coccidioidomycotic meningitis diagnosed within 8 weeks prior to enrolment.
  4. Ongoing symptoms due to coccidioidomycosis are such that the risk-benefit of treatment with an agent with a hepatic signal requiring careful monitoring is judged favorable based on meeting criteria
  5. Female patients must be non-lactating and at no risk of pregnancy for one of the following reasons:

    • for at least 1 year;
    • Post-hysterectomy and/or post-bilateral oophorectomy;
    • Of , with a negative urine or serum human chorionic gonadotropin pregnancy test at the screening visit and must be using one of listed below highly effective method of throughout the course of the study period and up to and including 30 days after stopping study drug

      • Established use of oral, injected, transdermal, intravaginal, or implanted hormonal methods of contraception associated with inhibition of ovulation
      • Placement of an intrauterine device or intrauterine hormone-releasing system
      • Male sterilization
      • Bilateral tubal occlusion
      • Sexual abstinence (reliable sexual abstinence is acceptable but periodic abstinence [e.g., calendar, ovulation, symptom-thermal, or post-ovulation methods] and withdrawal are not acceptable).
  6. Male patients with female partners of childbearing potential must either totally abstain from sexual intercourse or use a highly effective means of contraception throughout study participation and agree to continue its use for 30 days after stopping study drug and may not donate semen during this time.

Exclusion criteria

Exclusion Criteria:

  1. Patients who are unconscious.
  2. Patients who are pregnant or breastfeeding.
  3. Known history of allergy, , or any serious reaction to any component of the olorofim.
  4. Patients with or planned placement of indwelling CNS hardware (e.g. reservoirs, shunts, ventriculostomies, or external drainage tubes).
  5. Patients with a second fungal infection requiring systemic antifungal treatment or prophylaxis, other than Pneumocystis jirovecii infections and cutaneous fungal infections treated topically.
  6. Patients with microbiological findings (e.g., bacteriological, virological) or other potential conditions that are temporally related and suggest a different than study indication etiology.
  7. infection but not currently receiving antiretroviral therapy. In cases where HIV infection is first diagnosed at the same time as the invasive fungal infection, if antiretroviral therapy is commenced at the time of enrollment, then such patients are eligible for enrolment
  8. Any known or suspected medical condition or social circumstance of the patient that may jeopardize adherence to the protocol requirements or impede the accurate measurement of efficacy.
  9. Patients with a concomitant medical condition that, in the opinion of the Investigator, may be an unacceptable additional risk to the patient should he/she participate in the study.
  10. Patients who have received prior treatment with olorofim/F901318.
  11. Treatment with any drug within the 30 days prior to the first administration of study drug except for unblinded protocols (eg, open-label oncological regimen variations or biologic studies). Prior to enrolling patients who are on other open-label studies, it is the site's responsibility to ensure that the study criteria for that study allow for enrollment into this study.
  12. Patients receiving treatment limited to supportive care due to predicted short survival time.
  13. Patients with a baseline prolongation of using Fridericia's Correction Formula (QTcF) ≥ 500 msec, or at high risk for QT/QTc prolongation, eg,

    1. A family history of long QT syndrome
    2. Other known pro-arrhythmic conditions
    3. Risk factors for Torsade de Pointes (e.g., uncompensated heart failure, abnormal plasma potassium or magnesium levels that cannot be corrected, an unstable cardiac condition during the last 30 days).
  14. Evidence of hepatic dysfunction with any of the following abnormal laboratory parameters at screening:

    1. Total ≥ 2 × (ULN), OR
    2. (ALT) or aspartate transaminase (AST) ≥ 3 × ULN, OR
    3. Patients with known cirrhosis or chronic hepatic failure (regardless of ALT/AST/total bilirubin).

    Liver transplant recipients may be enrolled if their laboratory parameters do not meet the laboratory exclusions given above.

  15. Prohibited concomitant medications. Concomitant administration of inhibitors of human dihydro-orotate dehydrogenase (DHODH), teriflunomide, leflunomide, and systemic use of cannabis/cannabinoid preparations, including tetrahydrocannabinol (THC) and cannabidiol (CBD) are prohibited. There are currently no other absolutely prohibited concomitant medications for olorofim but there are medications with potentially significant drug-drug interactions (DDIs) with olorofim or SOC and the management of potential interactions should be considered before study enrollment.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    olorofim

    Participants will receive treatment with olorofim

    Drug: olorofim

Interventions

  • Single group study - all participants will receive olorofim treatment

06

What researchers measure

Primary outcomes

  1. Safety: Number of participants with ≥1 treatment-emergent adverse event

    Counts and proportions of participants experiencing at least one adverse event after initiation of olorofim, regardless of causality. Adverse events will be coded and graded according to CTCAE v5.0.

    Time frame: First dose through end of treatment and 4-week follow-up

Secondary outcomes

  1. Efficacy: Investigator-assessed clinical response over 24 weeks

    Proportion of participants with improvement or resolution of coccidioidal meningitis-related clinical signs and symptoms compared with baseline, as assessed by the investigator at protocol-specified visits.

    Time frame: Baseline through Week 24 (End of Treatment)

  2. Efficacy: Change from baseline in Coccidioides serum complement fixation titers

    Change in serum complement fixation titers from baseline, measured at scheduled study visits, as an indicator of mycological and disease response.

    Time frame: Baseline through Week 24

  3. Efficacy: Radiological response assessed by imaging

    Proportion of participants with stable or improved radiological findings related to coccidioidal meningitis on clinically indicated imaging studies compared with baseline.

    Time frame: Baseline through Week 24

  4. Efficacy: Investigator-assessed overall treatment response

    Proportion of participants with overall response based on integration of clinical status, radiological findings (if available), and mycological/serologic data, as assessed by the investigator using protocol-defined criteria.

    Time frame: Baseline through Week 24

  5. Efficacy: All-cause mortality

    Proportion of participants who die from any cause during treatment or follow-up.

    Time frame: Baseline through Week 24 and 4-week follow-up

  6. Patient-reported Outcome: Change from baseline in Modified Zubrod Performance Score

    Change from baseline in MZ-PS, a measure of functional performance status.

    Time frame: Baseline through Week 24

  7. Patient-reported Outcome: Change from baseline in Valley Fever Patient-Reported Outcomes (VF-PRO) score

    Change from baseline in VF-PRO questionnaire scores assessing symptom burden and quality of life related to coccidioidomycosis.

    Time frame: Baseline through Week 24

  8. Patient-reported Outcome: Change from baseline in Clinical Global Impression-Severity (CGI-S) and Patient Global Impression-Severity (PGI-S)

    Change from baseline in investigator-rated (CGI-S) and patient-reported (PGI-S) disease severity scores. (separate scales but reported similarly)

    Time frame: Baseline through Week 24

  9. ECG Sub-Study: Change from baseline in QTcF interval

    Change in QT interval corrected using Fridericia's formula (QTcF), measured using continuous Holter ECG monitoring and time-matched with plasma olorofim concentrations in a subset of participants.

    Time frame: Day 10-21 (single study day)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD), including the analyzable dataset and associated metadata, will be shared with the study collaborator, F2G Ltd., for purposes of regulatory support, safety evaluation, and further analysis related to olorofim. Data shared will not include direct identifiers and will be coded prior to transfer.

Supporting information: Clinical study report

Access criteria: Access to the de-identified IPD will be limited to F2G Ltd. and authorized third-party vendors acting on behalf of the collaborator, under data use agreements that specify permitted uses and prohibit re-identification. Data will not be made publicly available. Study results may be disseminated through scientific publications and presentations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Mar 2027, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2026
First posted
Feb 4, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Mar 15, 2027
CompletionEst.
Jun 15, 2027
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07385638
Lead sponsor
Fariba Donovan
Collaborators
F2G Biotech GmbH
Responsible party
Fariba Donovan (MD, PhD, University of Arizona) — Sponsor-investigator
First posted
Feb 4, 2026
Start date
Jun 1, 2026
Primary completion
Mar 15, 2027 (estimated)
Completion
Jun 15, 2027 (estimated)
Last update
Jul 27, 2026

Study contacts

Dakota Darby
Contact
dakotadarby@arizona.edu
5206268000
Fariba Donovan, MD, PhD
principal investigator · University of Arizona

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olorofim

Start the discussion